Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
Q32 Bio (Nasdaq: QTTB) has priced an underwritten public offering of 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants for 4,931,506 shares at $18.2499 per warrant, each warrant carrying a $0.0001 per share exercise price. The company also granted underwriters a 30-day option to buy up to 1,643,835 additional common shares at the public offering price, less underwriting discounts and commissions.
Gross proceeds are expected to be about $200 million, before fees and expenses, assuming no exercise of the underwriters’ option and excluding any warrant exercises. The offering, with all securities sold by Q32 Bio, is expected to close on or about July 16, 2026, subject to customary conditions. According to Q32 Bio, net proceeds will support working capital, research, clinical development and commercialization efforts, including advancing bempikibart into future clinical trials. The securities are being issued under an effective Form S-3 shelf registration statement declared effective on July 13, 2026.
Positive
- $200 million expected gross proceeds to strengthen capital position
- Flexible mix of 6.0M shares and 4.9M pre-funded warrants
- 30-day underwriter option for up to 1.64M additional shares
- Proceeds earmarked for R&D, clinical development and commercialization of bempikibart
Negative
- Equity and warrant issuance likely increases share count and dilutes existing holders
- Underwriting discounts, commissions and offering expenses reduce net proceeds below $200 million
News Explained
The financing is priced but not closed; its common shares and potentially exercised warrants would dilute existing holders if issued.
The
Under the underwritten structure, investment banks buy securities from Q32 Bio for resale, while underwriting fees and offering expenses reduce net proceeds below the approximately
On the same first-quarter cash-use basis, the gross amount equals 2837.8 days of operating cash use, compared with 720.1 days represented by cash and equivalents at
The final prospectus supplement will state the offering’s final terms, while the expected closing on or about
Sources and calculations
- Q32 Bio public offering pricing release (2026-07-14)
- Pre-funded warrant definition (2026-07-14)
- Dilution definition (2026-07-14)
- Underwritten offering definition (2026-07-14)
- Prospectus supplement purpose (2026-07-14)
- Q32 Bio first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $200,000,000 / ($6,343,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $50,751,000 / ($6,343,000 / 90) = [object Object]
Market reaction after Common stock and warrant public offering: QTTB -14.95% in the Jul 15 session
In the Jul 15 session, QTTB declined 14.95%, reflecting a significant negative market reaction. Argus tracked a peak move of +20.3% during that session. Argus tracked a trough of -20.0% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 13 | Proposed public offering | Negative | -0.0% | Company launched proposed $200 million underwritten offering of stock and warrants. |
| Feb 17 | Registered direct offering | Negative | +9.7% | Announced $10.5 million registered direct sale of common shares and pre-funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent capital-raising announcements have not produced consistently negative reactions, with one prior offering trading flat and another moving higher.
Key Terms
pre-funded warrants financial
underwritten public offering financial
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Morgan Stanley, Jefferies and Cantor are acting as joint book-running managers for the offering. Oppenheimer & Co. is also acting as a book-running manager for the offering, and H.C. Wainwright & Co. is acting as lead manager for the offering.
Q32 Bio intends to use the net proceeds of the offering for working capital purposes, including expenses related to research, clinical development and commercialization efforts including for supporting the advancement of bempikibart into future clinical trials.
The securities described above are being offered by Q32 Bio pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-297027) that was filed with the Securities and Exchange Commission (the "SEC") on June 25, 2026 and declared effective on July 13, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering have been filed with the SEC, and a final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, copies of the final prospectus supplement, and the accompanying prospectus relating to the offering may be obtained by visiting the SEC's website at www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor,
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
1National Alopecia Areata Foundation
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, the completion and timing of the underwritten public offering, the potential exercise by the underwriters of the option to purchase additional shares and the expected proceeds from the offering and the anticipated use of such proceeds. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies might be more costly than expected or might not yield anticipated results, that Q32 Bio may use its capital resources sooner than currently anticipated, that Q32 Bio may need additional funding to complete clinical studies, which may not be available on favorable terms or at all; as well as the risks and uncertainties identified in Q32 Bio's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and any subsequent filings Q32 Bio makes with the SEC. In addition, any forward-looking statements represent Q32 Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Except as required by applicable securities laws, Q32 Bio undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts:
Investors
Brendan Burns
Argot Partners
Q32Bio@argotpartners.com
Media
David Rosen
Argot Partners
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-announces-pricing-of-200-million-public-offering-of-common-stock-and-pre-funded-warrants-302825849.html
SOURCE Q32 Bio